The U.S. Food and Drug Administration recently expanded approval of the nasal spray SPRAVATO, a ketamine-derived drug, as a treatment for depression. A clinic in Denver is looking to help those ...

A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will be sold under the brand name Journavx.

Walmart, CVS, Amazon and other well known retailers may have carried the recalled product, which the FDA calls out unique ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.

(NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced two ...

The results, which come on the heels of the FDA’s approval of J&J’s esketamine nasal spray Spravato as a monotherapy for ...

A new study found that retirees who drank moderately had fewer depression symptoms than non-drinkers, but retirees who drank ...

People with treatment-resistant depression can now take Spravato's ketamine-derived nasal spray as a standalone treatment.

The FDA has approved the use of Spravato, an antidepressant nasal spray, as a standalone treatment for depression in the U.S. Sue Varma discusses why she supports the use of the drug and how it may ...

CIII allows people who have tried at least two oral antidepressants to use the spray on its own – without the need for more ...

The U.S. Food and Drug Administration (FDA) approved the antidepressant nasal spray Spravato as a standalone treatment for depression in adults.

(HealthDay News) — The US Food and Drug Administration has approved Spravato (esketamine) CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at ...